Apart from SCC, this peptide ligand of EGFr has potential applications in targeting treatments of patients with EGFr-positive malignancies, which include non-small cell lung cancer, esophageal, gastric, prostate, colorectal, bladder, pancreatic, ovarian and renal cancers. Here, EGFR is linked to renal carcinoma.